Vicore Pharma Holding AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2015
Net Income	-168.63	-310.94	-288.42	-296.48	-146.86	Upgrade
Depreciation & Amortization	2.24	3.42	3.61	3.6	3.54	Upgrade
Loss (Gain) From Sale of Assets	-	-	2	-	-	Upgrade
Asset Writedown & Restructuring Costs	-	62.55	-	-	-	Upgrade
Other Operating Activities	3.28	6.03	3.83	0.64	0.71	Upgrade
Change in Accounts Receivable	-35.6	-4.28	-1.6	-0.34	-3.87	Upgrade
Change in Accounts Payable	33.77	-6.36	-19.34	27.41	26.55	Upgrade
Operating Cash Flow	-164.95	-249.58	-299.92	-265.17	-119.94	Upgrade
Sale (Purchase) of Intangibles	-	-	-3	-	-3	Upgrade
Investment in Securities	149.04	-144.46	77	-7	7	Upgrade
Investing Cash Flow	149.04	-144.46	74	-7	4	Upgrade
Issuance of Common Stock	882.14	500.41	200	336	187.55	Upgrade
Other Financing Activities	-48.08	-29.55	-12.96	-17.82	-10.58	Upgrade
Financing Cash Flow	834.06	470.86	187.04	318.18	176.97	Upgrade
Foreign Exchange Rate Adjustments	4.23	-	1.48	-0.43	-	Upgrade
Net Cash Flow	822.38	76.82	-37.4	45.58	61.03	Upgrade
Free Cash Flow	-164.95	-249.58	-299.92	-265.17	-119.94	Upgrade
Free Cash Flow Margin	-150.85%	-	-	-	-	Upgrade
Free Cash Flow Per Share	-1.20	-2.58	-4.15	-3.81	-2.21	Upgrade
Cash Interest Paid	0.01	0	0.01	0.01	0.01	Upgrade
Levered Free Cash Flow	-111.57	-200.41	-195.17	-160.92	-71.86	Upgrade
Unlevered Free Cash Flow	-111.56	-200.41	-195.16	-160.92	-71.86	Upgrade
Change in Net Working Capital	2.33	10.18	20.96	-20.44	-23.79	Upgrade

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.